Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonist
- 1 January 1997
- journal article
- Published by Wiley
- Vol. 43 (1) , 49-54
- https://doi.org/10.1111/j.1365-2125.1997.tb00137.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical effects and mechanism of action of sumatriptan in migraineClinical Neurology and Neurosurgery, 1992
- Endocrine effects of sumatriptanThe Lancet, 1992
- Headache recurrence after subcutaneous sumatriptanThe Lancet, 1992
- Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraineTrends in Pharmacological Sciences, 1992
- Oral sumatriptan in acute migraineThe Lancet, 1991
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991
- A Randomized, Double-Blind Comparison of Sumatriptan and Cafergot in the Acute Treatment of MigraineEuropean Neurology, 1991
- The Clinical Pharmacology, Pharmacokinetics and Metabolism of SumatriptanEuropean Neurology, 1991
- Preclinical Studies on the Anti-Migraine Drug, SumatriptanEuropean Neurology, 1991
- Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster HeadacheClinical Pharmacokinetics, 1985